PTNPalatin Technologies Inc.

Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system. Its current portfolio centers on receptor-targeted therapeutics for obesity, rare neuroendocrine disorders, inflammatory conditions, autoimmune diseases, and ocular disorders. The company’s work includes product candidates and partnered programs designed to address areas with significant unmet medical need, with a focus on selective peptide and small-molecule approaches. Palatin Technologies also participates in collaboration and licensing activities that support its research and development efforts across multiple therapeutic areas. Based in Princeton, New Jersey, Palatin Technologies Inc. operates as a clinical-stage company within the healthcare sector, where it contributes to the development of novel treatments aimed at specialized patient populations.